Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing

Casandra

Casandra Test Code AR97351Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 3002714CPT Code 81450

Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing

Also known as: AML NGS

Clinical Use

Order Test

Use

This test is used to assess for single gene mutations, including substitutions and smaller insertions and deletions, that may have prognostic and/or therapeutic significance in acute myeloid leukemia (AML). AML is a genetically heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues, leading to impaired hematopoiesis and bone marrow failure. The panel provides a more cost-effective approach compared to multiple single gene tests and complements the morphologic and cytogenetic workup of myeloid malignancies.

Special Instructions

Testing is not New York state approved. Specimens from New York clients will be sent out to a New York state-approved laboratory. Patient consent forms for genetic testing are required for New York clients and must be kept on file by the ordering physician.

Limitations

Variants outside the targeted regions or below the limit of detection are not identified. Variants in regions that are not included in the preferred transcript for the targeted genes are not detected. Some variants may not be identified due to technical limitations, such as pseudogenes or repetitive regions. Insertion/deletion variants greater than 24bp may have reduced analytical sensitivity. NPM1 exon 1 is not sequenced due to technical limitations of the assay.

Test Details